Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro
Microbial Pathogenesis · 2025
DOI: 10.1016/j.micpath.2025.107593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Pathogenesis, 2025. Verfasst von Mayire Aizezi und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Cilnical Medicine Institute, The First Aff…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Bacterial Proteins, Cell Differentiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb), which is increasing year by year and brings great harm to human beings. Genomic analysis showed that compared with Mtb, some regions of differences (RD) were missing in the BCG genome, and Rv0222 was located in the RD4 region of Mtb. In our study, the recombinant Rv0222(rRv0222) protein was successfully constructed with pET32a as the expression vector. After stimulating mouse spleen cells with different concentrations of rRv0222, the cell proliferation rate was detected by CCK8 method. We found that the cell proliferation activity decreased with the increase of the concentration of rRv0222. The concentration of Th9-related cytokines was determined by ELISA, and it was found that the levels of IL-4, IL-9, IL-10 and TGF-β1 were increased. The expression of IL-9 and TGF-β1 mRNA was detected by RT-qPCR method, and it was found that the mRNA expression was increased. The proportion of Th9-related T cells was detected by flow cytometry. The results showed that the proportion of CD3+CD4+T cells in spleen lymphocytes decreased, and the proportion of CD4+IL-4+T and CD4+IL-9+T cells increased. Our study showed that the rRv0222 can up-regulate Th9 cell-related factors, inhibit cell proliferation, and regulate host immune cells, which provides a theoretical basis for elucidating the regulation of host immune response by Mtb, it may serve as both a vaccine candidate and a potential therapeutic target for TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Cilnical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, Chi…
- College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, China.
- Department of Respiratory Neurology, Affiliated Tumor Hospital of Xinjiang Medical University Urumqi, Xinjiang, China.
Zitieren
APA
Aizezi, M., Wusiman, A., Kuerban, K., Aimaierjiang, R., Tuohetaerbaike, B., Guo, B., & Aimulajiang, K. (2025). Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.107593
Vancouver
Aizezi M, Wusiman A, Kuerban K, Aimaierjiang R, Tuohetaerbaike B, Guo B, et al. Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro. Microbial Pathogenesis. 2025. doi:10.1016/j.micpath.2025.107593
BibTeX
@article{Aizezi2025,
author = {Aizezi, Mayire and Wusiman, Adelijiang and Kuerban, Kadierya and Aimaierjiang, Reyila and Tuohetaerbaike, Bahatibieke and Guo, Baoping and Aimulajiang, Kalibixiati},
title = {Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro},
journal = {Microbial Pathogenesis},
year = {2025},
doi = {10.1016/j.micpath.2025.107593}
}
EUVIMED